Evaluating Intestinal Microbiome and Immune Function in Lymphoma


About this study

The purpose of this study is to examine the microbiome and immune function in patients with active lymphoma, and in patients with a history of lymphoma who are in clinical remission.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients with a histologic diagnosis of:
    • Newly diagnosed;
    • Progressive;
    • Relapsed lymphoma (any NHL HL, or CLL histology) who are initiating or changing therapy (chemotherapy, radiotherapy, or clinical trial/ investigational agent), or who have measurable disease and are being expectantly monitored. Patients whose lymphoma is in remission and who are being monitored expectantly are eligible as a separate cohort.
  • Age > 18 years.
  • May be s/p autologous or allogeneic bone marrow transplant.
  • Ability to understand and willing to sign a written informed consent document.
  • Patients with a histologic diagnosis of relapsed lymphoma or multiple myeloma who are scheduled to undergo CAR T cell therapy (up to 25 patients).
  • Newly diagnosed, untreated DLBCL patients confirmed by pathologic review. 

​​Exclusion Criteria:

  • Patients already receiving any investigational agents or chemotherapy at time of baseline sample collection.
  • Medical illnesses with potential suppressive or activating impact on immune and bowel function as judged by the investigator.                               
  • Patients with CNS disease or lymphoma related to prior chemotherapy (new DLBCL cohort only).
  • Patients with hemoglobin level of 8 or below.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/17/23. Questions regarding updates should be directed to the study team contact.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Thomas Witzig, M.D.

Open for enrollment

Contact information:

Jacqueline Pyan

(507) 284-9050


More information


Publications are currently not available

Mayo Clinic Footer